|
|
||||||||
1 Departments of Pediatrics, Ophthalmology, and Pharmacology, Research Center of Hôpital Sainte-Justine, Montreal H3T 1C5; 2 Faculty of Biological Sciences, University of Montreal, Montreal H3C 3J7; and 3 Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6
| |
ABSTRACT |
|---|
|
|
|---|
We investigated if prostaglandins might regulate the
increased choroidal endothelial (e) nitric oxide synthase (NOS)
expression in the perinate. Prostaglandins, eNOS mRNA, immunoreactive
protein and activity, and nitrite [stable metabolite of nitric
oxide (NO)] production were markedly higher in newborn (1 day
old) than juvenile (6-8 wk old) pig choroid. Treatment of isolated
newborn choroids with the prostaglandin synthase inhibitor ibuprofen
for 24 h reduced eNOS mRNA and nitrite production to values in
juveniles. This effect was equally observed with the
PGD2 receptor (DP) blocker BW
A868C and was prevented by cotreatment with
PGD2 but not other prostaglandins;
similar observations were made on NOS activity in vivo.
PGD2 also increased eNOS
expression on choroids of juveniles, and this effect was blocked by BW
A868C. The manifestation of this upregulation of eNOS by
PGD2 on the control of choroidal vasomotor response was tested by using NO-dependent vasorelaxants, ACh,
bradykinin (Bk), and substance P (SP). ACh-, Bk-, and SP-elicited choroidal vasorelaxation was greater in saline-treated newborn than
juvenile pigs. Ibuprofen (24 h) decreased ACh-, Bk-, and SP-evoked
vasorelaxation in newborns, whereas
PGD2 increased that in juveniles
and prevented the ibuprofen-induced attenuated relaxation in newborns;
infusion of
N
-monomethyl-L-arginine
in choroids of those animals treated with PGD2 reversed the augmented
vasorelaxation to ACh, Bk, and SP. Finally,
PGD2-induced upregulation of NOS
in the perinate was also reflected by curtailed choroidal blood flow
autoregulatory response to increased perfusion pressure. In conclusion,
PGD2 exhibits a major role in
upregulating eNOS expression and activity in the choroid, which in turn
results in greater NO-mediated vasorelaxation; a new mechanism for eNOS
regulation via DP is hereby disclosed. The relationship between
PGD2 and eNOS in the developing
subject provides an explanation for the interactive role of these two factors in the absent choroidal blood flow autoregulation in the perinate.
endothelial nitric oxide synthase; newborn
| |
INTRODUCTION |
|---|
|
|
|---|
THE CHOROID IS A vascular tissue that provides the principal supply of O2 and nutrients to the retina (4). Despite the lower tissue O2 consumption of the perinate, its choroidal blood flow (ChBF) is relatively high compared with that in the adult, partly to compensate for the developing retinal vascular bed (19). Choroidal vasculature of the newborn, in contrast to that of the adult, also fails to constrict appropriately in response to augmented O2 and perfusion pressure (18, 19, 24). This failure to adequately control O2 delivery to the eye of the newborn could favor O2 toxicity (28) and has also been suggested to contribute to predisposing to retinopathy of prematurity (19, 20, 28). The relatively increased basal ChBF and lack of the latter to exhibit O2- and pressure-induced autoregulation in the newborn largely results from excess endothelial (e) nitric oxide synthase (NOS) activity, which generates higher levels of the vasorelaxant nitric oxide (NO; see Refs. 18 and 19). The mechanisms that regulate the ontogeny of NOS activity, particularly in the choroid, are not yet known.
In the developing subject, prostaglandins and NO seem to exhibit a comparable regulation of ChBF (10, 18). As seen with NO, prostaglandin formation is also increased in perinatal ocular tissues (1, 17). A role for prostaglandins in the regulation of inducible (i) NOS expression has been reported (3, 12, 27, 30). However, whether prostaglandins regulate the expression of the constitutive eNOS, specifically in the developing choroid, and the type of prostaglandin involved in this regulatory process are not known.
We therefore determined whether and which type of prostaglandin modulates eNOS expression, activity, and function in the choroid of newborn and juvenile pigs. Our data reveal that, specifically, PGD2 regulates the expression of eNOS in the developing choroid, which in turn affects vasomotor tone and ChBF autoregulation. These observations disclose a new regulatory mechanism of eNOS expression via a novel function for PGD2 via its receptor (DP).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals. Newborn (1-day-old) and juvenile (6- to 8-wk-old) Yorkshire pigs were used according to a protocol approved by the Animal Care Committee of Hôpital Sainte-Justine in accordance with the principles of the Guide to the Care and Use of Experimental Animals and guidelines of the Canadian Council on Animal Care. For in vitro experiments, anesthetized (2% halothane) pigs were killed with pentobarbital sodium (120 mg/kg intracardiac), and the eyes were quickly removed and placed in ice-cold Krebs buffer (pH 7.4) of the following composition (mmol/l): 120 NaCl, 4.5 KCl, 2.5 CaCl2, 1.0 MgSO4, 27 NaHCO3, 1.0 KH2PO4, and 11 glucose, to which was added 1.5 U/ml heparin. On choroids from these eyes, eNOS mRNA, immunoreactivity and activity, and nitrite production and prostaglandin levels were measured. Other choroids were first incubated with modulators of prostaglandin levels described below.
In vitro incubation of choroids.
Isolated newborn choroids were incubated for 24 h in DMEM culture
medium in the presence or absence of the prostaglandin synthase
inhibitor ibuprofen (10 µM), a combination of ibuprofen (10 µM) and
either PGD2,
16,16-dimethyl-PGE2, or
carbaprostacyclin (stable PGI2
analog; all at 1 µM), or only with the selective DP antagonist BW
A868C (1 µM; see Refs. 8 and 13). Choroids of juveniles
were similarly treated with PGD2 or a combination of PGD2 with BW
A868C. The 24-h treatment duration was based on pilot experiments which
revealed that acute (
2 h) administration of those agents were
ineffective in altering eNOS expression. At the end of the incubation,
tissues were processed to measure eNOS mRNA and nitrite production;
neuronal (n) NOS is not detectable in the isolated choroid (1).
Animal preparation for in vivo
experiments. Pigs were anesthetized with 2% halothane.
A catheter (Cathlon; Johnson & Johnson, Arlington, TX) was placed in a
femoral vein and secured to the animal with tape. Newborn animals were
randomly assigned to receive intravenously every 8 h for 24 h, saline,
ibuprofen (40 mg/kg), a combination of ibuprofen (40 mg/kg) with either
PGD2,
16,16-dimethyl-PGE2, or
carbaprostacyclin (each at 10 µg/kg), or the
PGD2 receptor blocker BW A868C (10 µg/kg); a few animals treated with both ibuprofen and
PGD2 also received the NOS
inhibitor
N
-monomethyl-L-arginine
(L-NMMA; 1 mg/kg) 30 min before hemodynamic studies. The
dose of ibuprofen was previously shown to decrease neonatal
prostaglandin levels to those of the adult (1, 2) and those of
prostaglandins and analogs to change prostaglandin levels and/or cause
effects in vivo (5, 23, 25). Juvenile pigs were treated with saline or
PGD2. At the end of the 24-h period, animals were either kept alive to study ChBF autoregulation or
were killed (120 mg/kg iv pentobarbital sodium) to obtain eyes to
measure choroidal NOS activity or perform vasomotor studies.
eNOS and destrin RNase protection
assays. Partial eNOS and destrin cDNAs were synthesized
by RT-PCR from porcine cerebellar total RNA. The primer pair for
porcine eNOS was 5'-GCT TTT
G AGC GAC-3' and
5'-GCC AGT
A CTC
TGG-3' (35). The primer pair for porcine destrin was 5'-ATG
ATG
TG AAA CC-3' and
5'-
T CGA TCT GTG
G-3'. The amplified products (0.4 kb) were digested with
appropriate restriction enzyme (underlined sequences in the primers
denote the restriction sites) and cloned into pGEM4 vector. The
nucleotide sequences of pig eNOS and destrin partial cDNAs were
determined by sequencing multiple clones using the T7 sequencing kit
(BRL Life Technologies, Burlington, ON, Canada).
[32P]cRNA probes for
eNOS and destrin were prepared using an in vitro transcription kit (Promega).
Total RNAs from choroid were separated into aliquots and subjected to RNase protection assays according to a published protocol with minor modifications (9). Briefly, 20 µg of total RNA were mixed with 105 counts/min of eNOS and destrin probes in 20 µl of hybridization buffer (80% deionized formamide, 40 mM PIPES, pH 6.8, 1 mM EDTA, and 0.4 M NaCl), denatured at 90°C for 5 min, and incubated overnight at 50°C. The RNA hybrids were digested with ribonuclease A (10 µg/ml) and ribonuclease T1 (200 U/ml) in 200 µl of digestion buffer (10 mM Tris · HCl, pH 7.5, 5 mM EDTA, and 0.3 M NaCl) for 30 min at 25°C, followed by precipitation of protected fragments (9). The protected RNA fragments were resolved on urea-6% polyacrylamide gels, and the bands were visualized by phosphorimaging (Molecular Dymamics) and quantified densitometrically.
eNOS Western blotting. Western blotting for choroidal eNOS was performed exactly as previously described (1).
Nitrite production. NO production was
estimated by determination of its stable metabolite, nitrite (33).
Measurement of nitrite production in isolated choroids was performed as
previously reported (1). NOS-dependent formation of NO was estimated as the difference in nitrite production in the absence or presence of
N
-nitro-L-arginine
(L-NA; 1 mM).
NOS activity. Total NOS activity in choroid was determined as the L-NA (1 mM)-sensitive production of L-[3H]citrulline from L-[3H]arginine as previously described (19); constitutive Ca2+-dependent NOS activity (largely eNOS in choroid; see Ref. 1) was determined after subtraction of Ca2+-independent iNOS activity (in presence of 0.5 mM EGTA) from total NOS activity.
Prostaglandin measurements. Choroidal
levels of PGE2,
PGD2, and
6-keto-PGF1
(stable metabolite
of PGI2) were measured by RIA
(1, 15).
Choroidal vasomotor responses.
Choroidal vasomotor response to agents that elicit their effects mostly
via NO was studied as previously described (1, 15). Hence, effects of
NO-dependent vasorelaxants ACh (14), bradykinin (Bk; see Ref. 37), and
substance P (SP; see Ref. 31) were determined on vascular tone of
choroids from newborn animals treated for 24 h with saline, ibuprofen, or a combination of ibuprofen and
PGD2; juvenile pigs were treated with saline or PGD2. The choroid
was perfused using a pulsatile minipump (Gilson) with Krebs buffer at
physiological (19) constant flow rates of ~0.20 ml/min in the newborn
and at ~0.57 ml/min in juveniles to produce a perfusion pressure of
60 and 67 mmHg (10, 19), respectively. Perfusion pressure was
continuously recorded using a pressure transducer (Perceptor DT)
connected immediately afferent to the choroid; accordingly, a decrease
in perfusion pressure reflects vasorelaxation and an increase reflects vasoconstriction. After stabilization of the preparation (~30 min),
U-46619 (0.1 µM) was added to the perfusate to evoke constriction; thereafter, cumulative concentrations
(10
12 to
10
5 M) of ACh, Bk, or SP
were added to the perfusate; in some tissues, the perfusate contained
L-NMMA (1 mM). Relaxation was calculated as the percent
reversal of U-46619-induced constriction, which was ~75-85% of
maximal U-46619-evoked constriction in both newborn and juvenile
preparations; constriction to U-46619 is unaffected by ibuprofen (2).
To ascertain that NO-dependent vasorelaxants produced a similar
comparative profile of action on newborn and juvenile preparations,
effects of ACh were tested on tissues preconstricted with 8 µM
phorbol 12-myristate 13-acetate (nonreceptor mediated), which exerts
similar (80% of maximum) constriction in choroids of newborns and
juveniles (2); results were comparable to those with U-46619.
Measurement of ChBF. Animals were
prepared to measure ChBF using the radiolabeled microsphere technique
exactly as described in detail elsewhere (10, 16, 18, 19). ChBF as a
function of changes in perfusion pressure was studied as reported (17, 18). Increased ocular perfusion pressure [OPP: mean blood
pressure (MBP)
intraocular pressure (IOP)]
was produced by inflating a balloon-tipped catheter placed in the
distal thoracic descending aorta through a femoral artery. Each animal
was subjected to stepwise acute increases in OPP preset at 90, 105, and
125 mmHg. These values varied by
5 mmHg on different animals;
baseline MBP was 68 ± 5 mmHg for all animals and was unaffected by
treatments. Once MBP remained steady (within 30 s after balloon
inflation), ~106 microspheres
(15 µm diameter) labeled with
141Ce,
113Sn, and
85Sr (NEN, Boston, MA) were
injected in a random sequence into the catheterized left ventricle.
Reference samples were appropriately collected over the following 70 s.
After the experiment, pigs were killed (120 mg/kg pentobarbital
sodium). Radioactivity in the choroid and the reference blood samples
was counted in a gamma scintillation counter (Cobra II; Canberra
Packard, Meridien, CT), and blood flow was calculated using an on-line
computer program (PCGERDA).
Statistical analysis. Data were analyzed by ANOVA, comparison among means test (Tukey-Kramer method), and Student's t-test. ChBF was analyzed by regression analysis as previously described (17, 18). The Pearson's product moment coefficient (r) was calculated. Linear regressions were compared by the regression equality test using the method of least squares. Data are presented as means ± SE. Statistical significance was set at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
eNOS expression and activity in choroid of newborn and
juvenile pig. Prostaglandin levels were four- to
sixfold higher in newborn than juvenile choroid (Fig.
1A).
This was associated with three- to fivefold greater eNOS mRNA,
immunoreactive protein and activity, and nitrite production in newborn
compared with juvenile tissue (Fig. 1,
B-F); >90% of NOS activity was
Ca2+ dependent (constitutive),
and, as we reported, nNOS was not detectable using selective nNOS
blockers and by immunoreactivity, confirming dominance of eNOS in this
vascular tissue (1, 19).
|
In vitro modulation of eNOS mRNA and nitrite
production by prostaglandins in the choroid. Incubation
of isolated newborn choroid with ibuprofen (10 µM) for 24 h (but not
2 h) caused a significant reduction in the expression of eNOS mRNA
and in nitrite production to levels observed in the juvenile (Fig.
2, A-C).
Effects of ibuprofen were prevented by cotreatment with
PGD2 but were unaltered by stable
analogs of other major prostaglandins,
16,16-dimethyl-PGE2 and
carbaprostacyclin, at similarly increased doses. Furthermore, the
selective DP antagonist BW A868C decreased eNOS mRNA and nitrite production to levels found in saline-treated juvenile and
ibuprofen-treated newborn choroids (Fig. 2,
A-C). Moreover, in choroids of
juveniles, PGD2, but not other
prostaglandins, increased nitrite production and eNOS mRNA, and this
effect was prevented by cotreatment of PGD2 with BW A868C to levels found
in ibuprofen-treated newborn choroids.
|
In vivo modulation of NOS activity in newborn
choroid. We examined whether in vitro effects of
PGD2 on eNOS mRNA and nitrite production are reflected more specifically on
Ca2+-dependent NOS activity in
vivo in the newborn. Treatment of neonatal pigs for 24 h with ibuprofen
reduced PGE2,
6-keto-PGF1
, and PGD2 levels in choroid,
respectively, to 1,408 ± 351, 704 ± 106, and 56 ± 11 pg/mg protein from those in saline-treated newborns (see Fig.
1A). This decrease in
prostaglandin levels was associated with a decrement in NOS activity to
levels found in the juvenile (Fig. 3). This
reduction in NOS activity was prevented by cotreatment with
PGD2 but not with
16,16-dimethyl-PGE2 or
carbaprostacyclin. Once again, the selective DP blocker BW A868C
reduced NOS activity to values in the juvenile and the
ibuprofen-treated newborn.
|
Choroidal vasomotor responses. To
determine if this upregulation of eNOS expression and activity by
PGD2 is manifested physiologically in the control of the choroidal vasomotor response, we tested if
NO-dependent vasorelaxation was affected by modulation of eNOS expression. ACh, Bk, and SP caused NO-dependent vasorelaxation as it
was inhibited by L-NMMA (Fig.
4). Treatment of newborns with ibuprofen
decreased vasorelaxation to ACh, Bk, and SP to values in juveniles
(Fig. 4); this effect was prevented by (24 h but not
2 h) cotreatment
with PGD2, consistent with
increased PGD2-dependent NOS
activity (Figs. 2 and 3). Correspondingly, juvenile animals treated (24 h) with PGD2 exhibited increased vasorelaxation to ACh, Bk, and SP, as seen in saline-treated newborns. Infusion of L-NMMA in choroids of animals treated with
PGD2 reversed the augmented
vasorelaxation to ACh, Bk, and SP (Fig. 4).
|
ChBF autoregulation. Because failure
of the newborn to autoregulate ChBF is largely due to increased NO
formation (18, 19), we tested if modulation of NOS by prostaglandins
affected, in turn, ChBF autoregulation; experiments were not conducted
in juveniles because other factors such as increased efficacy of
vasoconstrictors participate in the complex autoregulatory control of
the older subjects (25). Basal ChBF was 32 ± 3 and 29 ± 4 ml · min
1 · g
1,
respectively in newborn and juvenile saline-treated pigs; blood gases,
heart rate, and IOP remained stable throughout experiments. In
saline-treated newborn pigs, in contrast to juveniles
(r = 0.13-0.22,
P > 0.3; Fig.
5F),
ChBF increased linearly as a function of OPP over the entire range of
OPP studied (r = 0.82-0.96,
P < 0.01; Fig.
5A), whereas treatment of newborns
with ibuprofen or BW A868C (24 h) led ChBF to be maintained constant as
a function of OPP (r = 0.07-0.31,
P > 0.4; Fig. 5,
B and
D). Coadministration of
PGD2 with ibuprofen caused ChBF to
increase linearly with OPP as seen in saline-treated newborns
(r = 0.71-0.99,
P < 0.05; Fig. 5C); addition of L-NMMA
reduced basal ChBF to 16 ± 3 ml · min
1 · g
1,
increased MBP from 64 ± 4 to 83 ± 5 mmHg as expected (19), and
caused ChBF to remain stable as a function of OPP
(r = 0.10-0.30, P > 0.3; Fig.
5E). Regression coefficients for
newborn pigs treated with saline or ibuprofen plus
PGD2 differed significantly from juveniles and from newborns treated with ibuprofen, BW A868C, or
ibuprofen plus PGD2 plus
L-NMMA (P < 0.05, by
regression equality test).
|
| |
DISCUSSION |
|---|
|
|
|---|
Increased NOS activity in the newborn choroid exerts important functions by maintaining adequate ocular circulation during the development of the retinal vascular bed (18, 19, 21). However, as a result of this increased NO formation, the ChBF autoregulatory response to increased O2 and perfusion pressure is absent in the perinate (18, 19). The mechanisms that regulate NOS expression and activity in choroid during development are not known. Prostaglandin levels in choroid are also increased in the neonate, and these have equally been found to curtail ChBF autoregulation (1, 2, 10, 21). Prostaglandins, primarily PGE2, have been reported to regulate iNOS expression (3, 12, 27, 30). We therefore investigated if and which type of prostaglandins might govern the expression, specifically of eNOS in the developing choroid. Our findings reveal that high levels of PGD2 through its actions on DP regulate eNOS expression and activity in the choroid of the neonate, and this in turn affects choroidal vasomotor regulation.
Evidence that high levels of prostaglandins, specifically PGD2, modulate eNOS expression in the newborn choroid is based on the following observations. 1) Reduction in prostaglandin levels of the newborn by ibuprofen [sustained (24 h), but not acute] to levels in the juvenile caused a decrease in eNOS mRNA, protein, and NOS activity (Figs. 2 and 3) to values in the older subject. 2) Effects of ibuprofen were reproduced by the selective PGD2 receptor blocker BW A868C. 3) Ibuprofen-induced inhibition of eNOS expression in newborns was prevented specifically by PGD2 but not by other prostaglandins (even at high concentrations, 1 µM); this modulation of eNOS by PGD2 was observed in vitro and in vivo. 4) Because our data suggested that high PGD2 levels in the newborn upregulate eNOS expression, we tested if PGD2 can increase eNOS activity in the juveniles (which have low prostaglandin and NO formation); our observations supported this inference (Fig. 2). One may suggest that the reported role of estrogens in regulating eNOS activity in lung tissue and cells may in part be attributed to prostaglandins (26, 29); alternatively, prostaglandins and estrogens may facilitate each other in coordinating the control of eNOS expression.
An important finding in this study is that the regulation of eNOS expression by PGD2 in the choroid is reflected in the developmental control of vasomotor tone. It has previously been shown that increased NO formation in the newborn exerts a greater contribution on basal choroidal vascular tone than in that of the juvenile adult and also curtails the autoregulatory response (18, 19). Accordingly, a reduction in NOS activity after ibuprofen or BW A868C decreased effects of NO-dependent vasorelaxants and enhanced ChBF autoregulation (Figs. 4 and 5) as seen after treatment with NOS inhibitors (Refs. 18 and 19 and the present study). Conversely, addition of PGD2 (24 h) evoked a choroidal vasomotor control as seen in the saline-treated newborns. Interestingly, sustained inhibition of prostaglandin synthesis has been reported to improve the regulation of choroidal vasomotor tone in vivo in the newborn (10). The present study provides a mechanism by which prostaglandins, specifically PGD2, interact with NOS in the control of choroidal vascular tone, such that prostaglandins regulate NO formation and the latter exerts a major role in governing ChBF.
The mechanism responsible for PGD2 in inducing eNOS expression is not clear; however, certain inferences can be made. Although DP stimulation is mostly coupled to cAMP formation (11), a cAMP response element is not present on the eNOS promoter (32, 36), albeit the latter does contain a site for activator protein-1, which may be activated by cAMP-dependent protein kinase A-induced phosphorylation (6). Alternate possibilities include the activation directly of functional perinuclear prostanoid receptors, which have been shown to induce gene transcription (7). In support of this suggestion, inhibition of the prostaglandin transporter using bromcresol green (22) prevented PGD2-induced upregulation of eNOS expression in the choroid (unpublished observation).
In conclusion, our results reveal an important mechanism for the developmental regulation of eNOS by PGD2 in the choroid, which in turn confers a major role on vasomotor tone. The findings disclose a new mechanism for the regulation of eNOS expression, namely by PGD2 via DP. This relationship between PGD2 and eNOS provides an explanation for the interactive role of these two factors in curtailed ChBF autoregulation in the newborn (10, 18, 19). The findings may also have implications for understanding of retinal hyperoxygenation (10, 19), a predisposition to retinopathy of prematurity.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Hendrika Fernandez for technical assistance.
| |
FOOTNOTES |
|---|
This work was supported by grants from the Medical Research Council of Canada, the Heart and Stroke Foundation of Québec, the Hospital for Sick Children Foundation, the March of Dimes Birth Defects Foundation, the United Cerebral Palsy Foundation, the Fonds pour la Formation de Chercheurs et l'Aide à la Recherche, and the Fonds de la Recherche en Santé du Québec. I. Dumont is a recipient of a studentship from the Ministry of Indian and Northern Affairs, Canada, and P. Hardy of a fellowship award from the Medical Research Council of Canada.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: S. Chemtob, Research Center, Hôpital Sainte-Justine, Depts. of Pediatrics, Ophthalmology, and Pharmacology, 3175, Côte Sainte- Catherine, Montreal, Quebec, Canada, H3T 1C5 (E-mail: chemtobs{at}ere.umontreal.ca).
Received 19 April 1999; accepted in final form 11 August 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abran, D.,
I. Dumont,
P. Hardy,
K. G. Peri,
D. Y. Li,
S. Molotchnikoff,
D. R. Varma,
and
S. Chemtob.
Characterization and regulation of prostaglandin E2 receptor and receptor coupled functions in the choroidal vasculature of the pig during development.
Circ. Res.
80:
463-472,
1997.
2.
Abran, D.,
D. R. Varma,
and
S. Chemtob.
Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs.
Am. J. Physiol. Regulatory Integrative Comp. Physiol.
272:
R995-R1001,
1997
3.
Aeberhard, E. E.,
S. A. Henderson,
N. S. Arabolos,
J. M. Griscavage,
F. E. Castro,
C. T. Barret,
and
L. J. Ignarro.
Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene.
Biochem. Biophys. Res. Commun.
208:
1053-1059,
1995[ISI][Medline].
4.
Alm, A.,
and
A. Bill.
The oxygen supply to the retina. I. Effects of changes in intraocular and arterial blood pressures, and in arterial PO2 and PCO2 on the oxygen tension in the vitreous body of the cat.
Acta Physiol. Scand.
84:
261-274,
1972[ISI][Medline].
5.
Ando, T.,
T. Ichijo,
T. Katafuchi,
and
T. Hori.
Intracerebroventricular injection of prostaglandin E2 increases splenic sympathetic nerve activity in rats.
Am. J. Physiol. Regulatory Integrative Comp. Physiol.
269:
R662-R668,
1995.
6.
Barchowsky, A.,
S. R. Munro,
S. J. Morana,
M. P. Vincenti,
and
M. Treadwell.
Oxidant-sensitive and phosphorylation-dependent activation of NF-
B and AP-1 in endothelial cells.
Am. J. Physiol. Lung Cell. Mol. Physiol.
269:
L829-L836,
1995
7.
Bhattacharya, M.,
K. G. Peri,
G. Almazan,
A. Ribeiro-da-Silva,
H. Shichi,
Y. Durocher,
M. Abramovitz,
X. Hou,
D. R. Varma,
and
S. Chemtob.
Nuclear localization of prostaglandin E2 receptors.
Proc. Natl. Acad. Sci. USA
95:
15792-15797,
1998
8.
Bhattacherjee, P.,
L. Rhodes,
and
C. A. Paterson.
Prostaglandin receptors coupled to adenylyl cyclase in the iris-ciliary body of rabbits, cats and cows.
Exp. Eye Res.
56:
327-333,
1993[ISI][Medline].
9.
Bordonaro, M.,
C. F. Saccomanno,
and
J. L. Nordstrom.
An improved T1/A ribonuclease protection assay.
Biotechniques
16:
428-430,
1994[ISI][Medline].
10.
Chemtob, S.,
K. Beharry,
J. Rex,
T. Chatteejee,
D. R. Varma,
and
J. V. Aranda.
Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets.
Invest. Ophthalmol. Vis. Sci.
32:
1799-1807,
1991
11.
Coleman, R. A.,
W. Smith,
and
S. Narumiya VIII.
International Union of Pharmacology Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.
Pharmacol. Rev.
46:
205-229,
1994[ISI][Medline].
12.
Gaillard, T.,
A. Mulsch,
H. Klein,
and
K. Decker.
Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages.
Biol. Chem.
373:
897-902,
1992.
13.
Giles, H.,
P. Leff,
M. L. Bolofo,
M. G. Kelly,
and
A. D. Robertson.
The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.
Br. J. Pharmacol.
96:
291-300,
1989[ISI][Medline].
14.
Granstam, E.,
S. O. Granstam,
B. Fellstrom,
and
L. Lind.
Endothelium-dependent vasodilation in the uvea of hypertensive and normotensive rats.
Curr. Eye Res.
17:
189-196,
1998[ISI][Medline].
15.
Hardy, P.,
D. Abran,
X. Hou,
I. Lahaie,
K. G. Peri,
P. Asselin,
D. R. Varma,
and
S. Chemtob.
A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet.
Circ. Res.
83:
721-729,
1998
16.
Hardy, P.,
D. Abran,
D. Y. Li,
H. Fernandez,
D. R. Varma,
and
S. Chemtob.
Free radicals in retinal and choroidal blood flow autoregulation in the piglets interaction with prostaglandins.
Invest. Ophthalmol. Vis. Sci.
35:
580-591,
1994
17.
Hardy, P.,
M. Bhattacharya,
D. Abran,
K. G. Peri,
P. Asselin,
D. R. Varma,
and
S. Chemtob.
Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-1 and -2 inhibition.
Invest. Ophthalmol. Vis. Sci.
39:
1888-1898,
1998
18.
Hardy, P.,
A. M. Nuyt,
D. Abran,
J. St.-Louis,
D. R. Varma,
and
S. Chemtob.
Nitric oxide in retinal and choroidal blood flow autoregulation in newborn pigs: interactions with prostaglandins.
Pediatr. Res.
39:
487-493,
1996[ISI][Medline].
19.
Hardy, P.,
K. G. Peri,
I. Lahaie,
D. R. Varma,
and
S. Chemtob.
Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs.
Circ. Res.
79:
504-511,
1996
20.
Hardy, P.,
D. R. Varma,
and
S. Chemtob.
Control of cerebral and ocular blood flow autoregulation in neonates.
Pediatr. Clin. North Am.
44:
137-152,
1997[ISI][Medline].
21.
Jacot, J. L.,
J. T. O'Neill,
D. M. Scandling,
S. D. West,
and
J. E. McKenzie.
Nitric oxide modulation of retinal, choroidal, and anterior uveal blood flow in newborn piglets.
J. Ocul. Pharmacol. Ther.
14:
473-489,
1998[ISI][Medline].
22.
Kanai, N.,
R. Lu,
J. A. Satriano,
Y. Bao,
A. W. Wolkoff,
and
V. L. Schuster.
Identification and characterization of a prostaglandin transporter.
Science
268:
866-869,
1995
23.
Kennedy, T. G.,
and
P. E. Doktorcik.
Effects of analogues of prostaglandin E2 and F2a on the decidual cell reaction in the rat.
Prostaglandins
35:
207-219,
1998.
24.
Kiel, J. W.,
and
W. A. J. van Heuven.
Ocular perfusion pressure and choroidal blood flow in the rabbit.
Invest. Ophthalmol. Vis. Sci.
36:
579-585,
1995
25.
Li, D.,
P. Hardy,
D. Abran,
A. K. Martinez-Bermudez,
A. M. Guerguerian,
M. Bhattacharya,
G. Almazan,
K. Menezes,
K. G. Peri,
D. R. Varma,
and
S. Chemtob.
Key role for cyclooxygenase-2 in PGE2 and PGF2
receptor regulation and cerebral blood flow of the newborn.
Am. J. Physiol. Regulatory Integrative Comp. Physiol.
273:
R1283-R1290,
1997
26.
MacRitchie, A. N.,
S. S. Jun,
Z. Chen,
Z. German,
I. S. Yuhanna,
T. S. Sherman,
and
P. W. Shaul.
Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium.
Circ. Res.
81:
355-362,
1997
27.
Marotta, P.,
L. Sautebin,
and
M. Di. Rosa.
Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line.
Br. J. Pharmacol.
107:
640-641,
1992[ISI][Medline].
28.
McLeod, D. S.,
R. Brownstein,
and
G. A Lutty.
Vaso-obliteration in the canine model of oxygen-induced retinopathy.
Invest. Ophthalmol. Vis. Sci.
37:
300-311,
1996
29.
Myers, S. I.,
R. H. Turnage,
L. Bartula,
B. Kalley,
and
Y. Meng.
Estrogen increases male rat aortic endothelial (RAEC) PGI2 release.
Prostaglandins Leukot. Essent. Fatty Acids
54:
403-409,
1996[ISI][Medline].
30.
Raddassi, K.,
J. F. Petit,
and
S. Lemaire.
LPS-induced activation of primed murine peritoneal macrophages is modulated by prostaglandins and cyclic nucleotides.
Cell. Immunol.
149:
50-64,
1993[ISI][Medline].
31.
Rosenblum, W. I.,
T. Shimizu,
and
G. H. Nelson.
Endothelium-dependent effects of substance and calcitonin gene-related peptide on mouse pial arterioles.
Stroke
7:
1043-1047,
1993.
32.
Venema, R. C.,
K. Nishida,
R. W. Alexander,
D. G. Harrison,
and
T. J. Murphy.
Organization of the bovine gene encoding the endothelial nitric oxide synthase.
Biochim. Biophys. Acta
1218:
413-420,
1994[Medline].
33.
Verdon, C. P.,
B. A. Burton,
and
R. L. Prior.
Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Greiss reaction is used to assay for nitrite.
Anal. Biochem.
224:
502-508,
1995[ISI][Medline].
34.
Zhang, J. L.,
J. M. Patel,
and
E. R. Block.
Molecular cloning, characterization and expression of a nitric oxide synthase from porcine pulmonary artery endothelial cells.
Comp. Biochem. Physiol. A Physiol.
116:
485-491,
1996.
35.
Zhang, R.,
W. Min,
and
W. C. Sessa.
Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells.
J. Biol. Chem.
270:
15320-15326,
1995
36.
Zhu, P.,
J. L. Beny,
J. Flammer,
T. F. Lüscher,
and
I. O. Haefliger.
Relaxation by bradykinin in porcine ciliary artery. Role of nitric oxide and K+ channels.
Invest. Ophthalmol. Vis. Sci.
38:
1761-1767,
1997
This article has been cited by other articles:
![]() |
H. Yoshida, T. Kubota, and J. M. Krueger A cyclooxygenase-2 inhibitor attenuates spontaneous and TNF-{alpha}-induced non-rapid eye movement sleep in rabbits Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R99 - R109. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Checchin, X. Hou, P. Hardy, D. Abran, T. Najarian, M. H. Beauchamp, S. G. Bernier, F. Gobeil Jr, C. Quiniou, D. R. Varma, et al. PGE2-Mediated eNOS Induction in Prolonged Hypercapnia Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1558 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Wright, D. Abran, M. Bhattacharya, X. Hou, S. G. Bernier, A. Bouayad, J.-C. Fouron, A. Vazquez-Tello, M. H. Beauchamp, R. I. Clyman, et al. Prostanoid receptors: ontogeny and implications in vascular physiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1343 - R1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hardy, D. Lamireau, X. Hou, I. Dumont, D. Abran, A.-M. Nuyt, D. R. Varma, and S. Chemtob Major role for neuronal NO synthase in curtailing choroidal blood flow autoregulation in newborn pig J Appl Physiol, October 1, 2001; 91(4): 1655 - 1662. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Najarian, A. M. Marrache, I. Dumont, P. Hardy, M. H. Beauchamp, X. Hou, K. Peri, F. Gobeil Jr, D. R. Varma, and S. Chemtob Prolonged Hypercapnia-Evoked Cerebral Hyperemia via K+ Channel- and Prostaglandin E2-Dependent Endothelial Nitric Oxide Synthase Induction Circ. Res., December 8, 2000; 87(12): 1149 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ovadia, J. M. Bekker, R. K. Fitzgerald, A. Kon, S. Thelitz, M. J. Johengen, K. Hendricks-Munoz, R. Gerrets, S. M. Black, and J. R. Fineman Nitric oxide-endothelin-1 interactions after acute ductal constriction in fetal lambs Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H862 - H871. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |